GlassScriptPhysician profile
Kathleen B Risley
NPI 1245266659
$2,216.82
in general payments reported to CMS, 2019-2025
24 companies · $368 in 2025
The $368 reported for 2025 was more than what 79% of Women'S Health (Nurse Practitioner) providers received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $213 · 2022: $354 · 2023: $657 · 2024: $625 · 2025: $368.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,556 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,555.66 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $442.24 | 2022-2025 | |
| Astellas Pharma US INC | $296.18 | 2021-2025 | Veozah, Myrbetriq |
| Amgen INC. | $212.82 | 2021-2024 | Evenity, Prolia |
| Sumitomo Pharma America, INC. | $180.66 | 2023-2025 | Myfembree |
| Abbvie INC. | $141.55 | 2021-2025 | |
| Evofem Biosciences, INC. | $127.75 | 2021-2025 | Phexxi, Solosec, Phexx |
| Bayer Healthcare Pharmaceuticals INC. | $100.20 | 2021-2025 | |
| Exeltis, USA INC. | $91.41 | 2021-2025 | Slynd |
| Novo Nordisk INC | $71.11 | 2023-2025 | Wegovy |
| Millicent US INC | $70.19 | 2024-2025 | Intrarosa, Femlyv |
| Myovant Sciences INC. | $70.12 | 2021-2022 | |
| Hologic Sales and Service, LLC | $61.60 | 2022-2024 | Thinprep 2000 Processor, Aptima, Third Wave |
| Organon LLC | $55.32 | 2023 | Nexplanon |
| Myriad Women'S Health, INC. | $51.63 | 2023 | Myrisk |
| Biohaven Pharmaceutical Holding Company LTD. | $51.29 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $38.42 | 2024 | Tymlos |
| Therapeuticsmd, INC. | $30.43 | 2021-2022 | |
| Avion Pharmaceuticals | $24.65 | 2023 | Balcoltra |
| Sage Therapeutics, LLC | $22.24 | 2025 | Zurzuvae |
| Lupin INC. | $22.08 | 2021 | |
| Virtus Pharmaceuticals LLC | $16.26 | 2021 | |
| Pfizer INC. | $14.53 | 2023 | |
| Aspira Women'S Health INC | $12.25 | 2022 | |
| Agile Therapeutics, INC. | $11.89 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathleen Risley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.